Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancerMaria Vittoria Dieci, Valentina Guarneri, PierFranco Conte et al.|Annals of Oncology|2019Cited by 96
Immune characterization of breast cancer metastases: prognostic implicationsMaria Vittoria Dieci, Valentina Guarneri, Vassilena Tsvetkova et al.|Breast Cancer Research|2018Cited by 89
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluationAleix Prat, PierFranco Conte, Luís Manso et al.|The Lancet Oncology|2020Cited by 75
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trialValentina Guarneri, PierFranco Conte, Maria Vittoria Dieci et al.|European Journal of Cancer|2021Cited by 42
Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancerGaia Griguolo, Valentina Guarneri, Maria Vittoria Dieci et al.|npj Breast Cancer|2021Cited by 25